Krystal Biotech Q3 EPS Forecast Decreased by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at William Blair cut their Q3 2025 earnings estimates for Krystal Biotech in a research note issued to investors on Friday, October 10th. William Blair analyst S. Corwin now expects that the company will post earnings of $1.11 per share for the quarter, down from their prior estimate of $1.14. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s FY2025 earnings at $5.16 EPS.

A number of other equities analysts also recently weighed in on the company. Chardan Capital lowered their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Citigroup restated a “neutral” rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $209.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $188.05 on Monday. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 38.22 and a beta of 0.64. The firm’s 50-day moving average is $157.48 and its 200-day moving average is $151.04.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analysts’ expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new position in shares of Krystal Biotech during the first quarter worth approximately $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after purchasing an additional 365,304 shares during the period. S Squared Technology LLC increased its stake in shares of Krystal Biotech by 2.1% during the first quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock worth $17,528,000 after purchasing an additional 2,000 shares during the period. Tempus Wealth Planning LLC bought a new position in shares of Krystal Biotech during the second quarter worth approximately $327,000. Finally, Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).